Response rates of 13% (head and neck squamous cell cancer), 25%-40% (renal cell cancer), and 31% (microsatellite-unstable colon cancers) have been reported with PD-1 blockade [23–25]. Here, PDCD1 is linked to malignant colon neoplasm.